490 Participants Needed

B-SAFER Technique for Aortic Dissection

(B-SAFER Trial)

ER
YK
Overseen ByYuki Kuramochi, BSN, RN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Eric Roselli, M. D.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

A prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

What data supports the effectiveness of the B-SAFER treatment for aortic dissection?

The B-SAFER treatment, which is a type of frozen elephant trunk (FET) technique, has shown promising early results in treating complex aortic diseases, as it combines elements of stented anastomosis and hybrid stent grafts. Studies on similar FET techniques have demonstrated positive outcomes in both acute and chronic aortic dissections, suggesting potential effectiveness for B-SAFER in aortic dissection cases.12345

Is the B-SAFER technique generally safe for humans?

The B-SAFER technique, also known as the frozen elephant trunk repair, has been studied for various aortic conditions and is considered favorable and safe, although some adverse events have been noted with certain grafts. Safety has been associated with the complexity of the procedure and the specific techniques used to manage different parts of the aorta.24567

What makes the B-SAFER treatment unique for aortic dissection?

The B-SAFER treatment is unique because it combines a branched stented anastomosis with a frozen elephant trunk repair, which allows for total arch replacement without unnecessary exposure of cervical arteries, potentially reducing surgical risk compared to conventional methods.15789

Research Team

ER

Eric Roselli, M. D.

Principal Investigator

The Cleveland Clinic

Eligibility Criteria

This trial is for adults over 18 with a life expectancy of more than two years who need repair or replacement of the thoracic aorta due to conditions like aneurysms, dissections, or congenital diseases. Participants must be able to consent and not have device sensitivities, uncorrectable bleeding disorders, active infections that could affect surgery outcomes, involvement in other studies with investigational products within the last six months, medical issues affecting trial participation, pregnancy, or severe brain malperfusion.

Inclusion Criteria

I need surgery for a serious problem with the main artery in my chest.
Subject is willing and able to give written informed consent to participate in the study or the subject's legally authorized representative has given written informed consent for the subject to participate in the study
I am 18 years old or older.
See 1 more

Exclusion Criteria

I cannot undergo major surgery that stops my blood circulation.
I am not in a coma or have severe, untreatable brain damage.
Subject has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- procedure
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Implantation of a physician-modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments

Hospital stay (up to 1 month)
In-hospital procedure

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of device functionality and monitoring for adverse events

36 months
Regular follow-up visits with CT imaging assessments

Treatment Details

Interventions

  • B-SAFER
Trial OverviewThe B-SAFER clinical trial tests a new hybrid surgical technique for repairing complex thoracic aortic pathologies. It's designed for patients requiring repair near the arch proximal to the innominate artery origin. This single-center study is prospective (looking forward in time), non-blind (patients and researchers know what treatment is given), and non-randomized (patients are not chosen by chance for different treatments).
Participant Groups
1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Implantation of a physician-modified endovascular stentgraft(s) to treat the proximal aorta in subjects with aortic disease involving multiple segments.

B-SAFER is already approved in United States for the following indications:

🇺🇸
Approved in United States as B-SAFER for:
  • Acute Aortic Dissection
  • Chronic Aortic Dissection
  • Degenerative Aortic Aneurysm
  • Congenital Aortic Arch Disease

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eric Roselli, M. D.

Lead Sponsor

Trials
1
Recruited
490+

The Cleveland Clinic

Collaborator

Trials
1,072
Recruited
1,377,000+

Findings from Research

The study involved 109 patients with non-acute DeBakey type I aortic dissection, using a new soft distal dissection-specific hybrid stent graft, which showed no significant early outcome differences compared to traditional stent grafts.
The soft distal stent graft demonstrated a 100% freedom from distal complications, suggesting it may be more effective in preventing new entry points in the aorta compared to stiffer grafts, although long-term outcomes are still needed for a comprehensive evaluation.
A new dissection-specific hybrid stent graft for patients with DeBakey type I aortic dissection.Charchyan, E., Breshenkov, D., Belov, Y.[2022]
In a study of 426 patients with acute type A aortic dissection, the frozen elephant trunk (FET) technique showed no significant difference in 30-day mortality or neurological dysfunction compared to other surgical methods.
However, long-term survival rates were significantly better for patients who underwent the FET procedure, indicating its potential benefits for improved outcomes in this high-risk population.
Early and long-term results of total arch replacement with the frozen elephant trunk technique for acute type A aortic dissection.Yoshitake, A., Tochii, M., Tokunaga, C., et al.[2022]
The 4-branched graft inversion technique used during total arch replacement for acute aortic dissection resulted in shorter circulatory and cardiac arrest times compared to the conventional method, suggesting improved efficiency in the surgical procedure.
This technique demonstrated effective hemostasis without increasing the risk of postoperative complications, making it a viable option for patients undergoing this complex surgery.
Four-branched graft inversion technique for the distal anastomosis in acute aortic dissection.Zou, Y., Teng, P., Ma, L.[2022]

References

A new dissection-specific hybrid stent graft for patients with DeBakey type I aortic dissection. [2022]
Early and long-term results of total arch replacement with the frozen elephant trunk technique for acute type A aortic dissection. [2022]
Four-branched graft inversion technique for the distal anastomosis in acute aortic dissection. [2022]
The Frozen Elephant Trunk Technique for the Treatment of Type B and Type Non-A Non-B Aortic Dissection. [2022]
Branched stented anastomosis frozen elephant trunk repair: Early results from a physician-sponsored investigational device exemption study. [2023]
Early outcomes of the Frozenix J-graft with exclusion of the non-stent part at a single center. [2022]
Use of On-Site Digital Subtraction Angiography for Left Subclavian Artery Management During Hybrid Aortic Arch Repair in DeBakey I Dissection. [2022]
Total arch replacement with extended branched stented anastomosis frozen elephant trunk repair for type A dissection improves operative outcome. [2023]
Follow-up outcomes after the frozen elephant trunk technique in chronic type B dissection. [2022]